HK1206341A1 - Substituted pyrazole compounds as lpar antagonists - Google Patents

Substituted pyrazole compounds as lpar antagonists Download PDF

Info

Publication number
HK1206341A1
HK1206341A1 HK15106926.9A HK15106926A HK1206341A1 HK 1206341 A1 HK1206341 A1 HK 1206341A1 HK 15106926 A HK15106926 A HK 15106926A HK 1206341 A1 HK1206341 A1 HK 1206341A1
Authority
HK
Hong Kong
Prior art keywords
phenyl
methyl
pyrazol
acid
biphenyl
Prior art date
Application number
HK15106926.9A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬．迪姆斯．加布里埃爾
斯蒂芬．迪姆斯．加布里埃尔
馬修．邁克爾．漢密爾頓
马修．迈克尔．汉密尔顿
錢義民
钱义民
阿奇尤特哈拉.西杜瑞
Original Assignee
霍夫曼-拉罗奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1206341(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 霍夫曼-拉罗奇有限公司 filed Critical 霍夫曼-拉罗奇有限公司
Publication of HK1206341A1 publication Critical patent/HK1206341A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK15106926.9A 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists HK1206341A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661958P 2012-06-20 2012-06-20
US61/661,958 2012-06-20
PCT/EP2013/062458 WO2013189862A1 (en) 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
HK1206341A1 true HK1206341A1 (en) 2016-01-08

Family

ID=48656033

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106926.9A HK1206341A1 (en) 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists

Country Status (22)

Country Link
US (1) US20150259295A1 (cs)
EP (1) EP2864294A1 (cs)
JP (1) JP2015520201A (cs)
KR (1) KR20150011003A (cs)
CN (1) CN104411690A (cs)
AU (1) AU2013279510A1 (cs)
BR (1) BR112014031108A2 (cs)
CA (1) CA2869602A1 (cs)
CL (1) CL2014003242A1 (cs)
CO (1) CO7160077A2 (cs)
CR (1) CR20140516A (cs)
EA (1) EA201492283A1 (cs)
HK (1) HK1206341A1 (cs)
IL (1) IL236091A0 (cs)
IN (1) IN2014DN09347A (cs)
MA (1) MA37765A1 (cs)
MX (1) MX2014014105A (cs)
PE (1) PE20142445A1 (cs)
PH (1) PH12014502364A1 (cs)
SG (1) SG11201407229UA (cs)
UA (1) UA109867C2 (cs)
WO (1) WO2013189862A1 (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014003499A2 (pt) 2011-08-15 2017-06-13 Intermune Inc compostos ou sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas e respectivos usos de quantidades eficazes e métodos para tratar, prevenir, reverter, parar ou retardar a prograssão de doença ou condição selecionada de fibrose, câncer ou distúrbios respiratórios e modular a atividade de receptor em célula
EA033923B1 (ru) 2013-03-15 2019-12-10 Эпиджен Байосайенсиз, Инк. Гетероциклические соединения, применимые в лечении заболеваний
RU2689315C2 (ru) 2014-06-27 2019-05-27 Убе Индастриз, Лтд. Соль гетероциклического соединения, замещенного галогеном
WO2019126085A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
WO2021247215A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
EP4337641A1 (en) * 2021-05-11 2024-03-20 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
JP7709612B2 (ja) 2021-12-08 2025-07-16 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063241A1 (ja) * 2003-12-26 2005-07-14 Ono Pharmaceutical Co., Ltd. ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
IN2012DN00754A (cs) * 2009-08-04 2015-06-19 Amira Pharmaceuticals Inc
EA201390821A1 (ru) * 2010-12-07 2013-10-30 Амира Фармасьютикалс, Инк. Антагонисты рецепторов лизофосфатидной кислоты и их применение
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
BR112014003499A2 (pt) * 2011-08-15 2017-06-13 Intermune Inc compostos ou sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas e respectivos usos de quantidades eficazes e métodos para tratar, prevenir, reverter, parar ou retardar a prograssão de doença ou condição selecionada de fibrose, câncer ou distúrbios respiratórios e modular a atividade de receptor em célula

Also Published As

Publication number Publication date
SG11201407229UA (en) 2014-12-30
CA2869602A1 (en) 2013-12-27
BR112014031108A2 (pt) 2017-06-27
EP2864294A1 (en) 2015-04-29
EA201492283A1 (ru) 2015-04-30
KR20150011003A (ko) 2015-01-29
UA109867C2 (ru) 2015-10-12
MX2014014105A (es) 2015-03-05
WO2013189862A1 (en) 2013-12-27
IL236091A0 (en) 2015-02-01
PE20142445A1 (es) 2015-01-28
AU2013279510A1 (en) 2014-10-16
MA37765A1 (fr) 2017-04-28
CL2014003242A1 (es) 2015-03-20
JP2015520201A (ja) 2015-07-16
US20150259295A1 (en) 2015-09-17
CN104411690A (zh) 2015-03-11
IN2014DN09347A (cs) 2015-07-17
PH12014502364A1 (en) 2015-01-12
CR20140516A (es) 2014-12-01
CO7160077A2 (es) 2015-01-15

Similar Documents

Publication Publication Date Title
HK1206341A1 (en) Substituted pyrazole compounds as lpar antagonists
US9321738B2 (en) N-alkyltriazole compounds as LPAR antagonists
JP6854386B2 (ja) リゾホスファチジン酸受容体１（ｌｐａｒ１）阻害剤化合物
US9604940B2 (en) 2-aminopyrazine derivatives as CSF-1R kinase inhibitors
HK1206339A1 (en) N-aryltriazole compounds as lpar antagonists
TW202128644A (zh) 作為lpa受體拮抗劑之三唑胺基甲酸酯吡啶基磺醯胺及其用途
US11020380B2 (en) Therapeutic compounds
KR20130118385A (ko) 글루카곤 수용체 조절자
JP5329656B2 (ja) イミダゾリジン誘導体
AU2016273360A1 (en) ROR gamma (RORy) modulators
JP2023538199A (ja) 化合物およびｍｉｆ阻害剤としての用途
JP7114591B2 (ja) Ｇｓｋ－３阻害剤
US7790754B2 (en) Alpha-hydroxy amides as bradykinin antagonists or inverse agonists
HK1206356A1 (en) Lpar - substituted cyanopyrazole compounds
US20170305915A1 (en) Indazole and indole derivatives as inhibitors of retinoic acid relates orphan receptor gamma (ror gamma) for the treatment of immune-related diseases